HK1220697A1 - 肽組合物 - Google Patents
肽組合物Info
- Publication number
- HK1220697A1 HK1220697A1 HK16108645.4A HK16108645A HK1220697A1 HK 1220697 A1 HK1220697 A1 HK 1220697A1 HK 16108645 A HK16108645 A HK 16108645A HK 1220697 A1 HK1220697 A1 HK 1220697A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- peptide compositions
- peptide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361790469P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/028590 WO2014144260A1 (en) | 2013-03-15 | 2014-03-14 | Peptide compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1220697A1 true HK1220697A1 (zh) | 2017-05-12 |
Family
ID=50588892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16108645.4A HK1220697A1 (zh) | 2013-03-15 | 2016-07-20 | 肽組合物 |
Country Status (11)
Country | Link |
---|---|
US (3) | US10196425B2 (zh) |
EP (2) | EP3450449A3 (zh) |
JP (3) | JP6622690B2 (zh) |
CN (3) | CN105492456A (zh) |
AU (5) | AU2014227712B2 (zh) |
CA (1) | CA2906694A1 (zh) |
ES (1) | ES2693761T3 (zh) |
HK (1) | HK1220697A1 (zh) |
RU (2) | RU2020120797A (zh) |
TR (1) | TR201815173T4 (zh) |
WO (1) | WO2014144260A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3539551T3 (pl) | 2011-12-29 | 2022-02-21 | Rhythm Pharmaceuticals, Inc. | Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli |
BR112015023409B1 (pt) | 2013-03-15 | 2023-11-28 | Rhythm Metabolic, Inc. | Complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo |
EP3450449A3 (en) | 2013-03-15 | 2019-06-12 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
CA3000670A1 (en) * | 2015-09-30 | 2017-04-06 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
US11591367B2 (en) * | 2016-10-04 | 2023-02-28 | Dsm Ip Assets B.V. | Melanocortin-1-receptor agonists |
MA49883A (fr) * | 2017-03-15 | 2021-04-21 | Novo Nordisk As | Composés bicycliques aptes à se lier au récepteur de mélanocortine 4 |
WO2019195756A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
WO2020053414A1 (en) * | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
CN113332416B (zh) * | 2021-05-17 | 2022-02-22 | 宁波大学 | 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用 |
CN113209270B (zh) * | 2021-05-17 | 2022-02-22 | 宁波大学 | 丙谷二肽在制备防治急性肝衰竭药物中的应用 |
CN116789802A (zh) * | 2023-06-25 | 2023-09-22 | 湖北省农业科学院畜牧兽医研究所 | 一种山羊mc4r增强型突变体及其应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3851002T2 (de) * | 1987-05-22 | 1995-02-02 | University Patents, Inc., Westport, Conn. | Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung. |
US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
GB9827500D0 (en) * | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
AU2001284026B2 (en) * | 2000-08-30 | 2007-03-01 | F. Hoffmann-La Roche Ag | Cyclic peptides having melanocortin-4 receptor agonist activity |
US7345144B2 (en) * | 2001-07-11 | 2008-03-18 | Palatin Technologies, Inc. | Cyclic peptides for treatment of cachexia |
IL159797A0 (en) | 2001-07-11 | 2004-06-20 | Palatin Technologies Inc | Linear and cyclic melanocortin receptor-specific peptides |
US7342089B2 (en) * | 2001-07-11 | 2008-03-11 | Palatin Technologies, Inc. | Cyclic peptides for treatment for cachexia |
US7034004B2 (en) * | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
FR2851563B1 (fr) | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
FR2852957B1 (fr) | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
JP2006527772A (ja) * | 2003-06-19 | 2006-12-07 | イーライ リリー アンド カンパニー | メラノコルチン3受容体(mc3r)作用薬ペプチドの用途 |
AU2004251616A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
FR2862971B1 (fr) | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
US8343031B2 (en) * | 2004-03-23 | 2013-01-01 | Michael Gertner | Obesity treatment systems |
FR2872165B1 (fr) | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | Nouveaux derives de pyrimido-benzimidazole |
EP2286825B1 (en) | 2005-07-08 | 2016-09-28 | Ipsen Pharma | Melanocortin receptor ligands |
WO2007008684A2 (en) | 2005-07-08 | 2007-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Ligands of melanocortin receptors |
TWI364290B (en) | 2007-05-25 | 2012-05-21 | Ipsen Pharma Sas | Melanocortin receptor ligands modifled with hydantoin |
EP2167112A4 (en) | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
CA2952095C (en) | 2007-11-05 | 2020-02-18 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
US20090305960A1 (en) * | 2008-06-09 | 2009-12-10 | Palatin Technologies, Inc | Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669 |
UY32690A (es) * | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
EP2440227B1 (en) | 2009-06-08 | 2017-10-18 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
CN102548399A (zh) * | 2009-08-05 | 2012-07-04 | 益普生制药股份有限公司 | 黑皮质素治疗血脂异常的用途 |
EP2501225B1 (en) | 2009-11-16 | 2017-11-01 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
US20120226018A1 (en) | 2009-11-16 | 2012-09-06 | Ipsen Pharma, S.A.S. | Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 |
WO2012172433A2 (en) | 2011-06-14 | 2012-12-20 | Ipsen Pharma S.A.S. | A sustained-release composition containing peptides as active ingredient |
EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
EP3450449A3 (en) * | 2013-03-15 | 2019-06-12 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
BR112015023409B1 (pt) * | 2013-03-15 | 2023-11-28 | Rhythm Metabolic, Inc. | Complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo |
-
2014
- 2014-03-14 EP EP18183527.3A patent/EP3450449A3/en active Pending
- 2014-03-14 CN CN201480026843.7A patent/CN105492456A/zh active Pending
- 2014-03-14 CN CN202410043141.5A patent/CN118240012A/zh active Pending
- 2014-03-14 JP JP2016502840A patent/JP6622690B2/ja active Active
- 2014-03-14 WO PCT/US2014/028590 patent/WO2014144260A1/en active Application Filing
- 2014-03-14 US US14/775,916 patent/US10196425B2/en active Active
- 2014-03-14 CA CA2906694A patent/CA2906694A1/en active Pending
- 2014-03-14 RU RU2020120797A patent/RU2020120797A/ru unknown
- 2014-03-14 TR TR2018/15173T patent/TR201815173T4/tr unknown
- 2014-03-14 RU RU2015145593A patent/RU2725150C2/ru active
- 2014-03-14 CN CN202410043113.3A patent/CN118271400A/zh active Pending
- 2014-03-14 AU AU2014227712A patent/AU2014227712B2/en active Active
- 2014-03-14 ES ES14719988.9T patent/ES2693761T3/es active Active
- 2014-03-14 EP EP14719988.9A patent/EP2970388B1/en active Active
-
2016
- 2016-07-20 HK HK16108645.4A patent/HK1220697A1/zh unknown
-
2018
- 2018-10-30 AU AU2018256493A patent/AU2018256493A1/en not_active Abandoned
- 2018-12-11 US US16/216,116 patent/US10858399B2/en active Active
-
2019
- 2019-06-19 JP JP2019113626A patent/JP7046871B2/ja active Active
-
2020
- 2020-05-22 AU AU2020203353A patent/AU2020203353A1/en not_active Abandoned
- 2020-10-26 US US17/080,293 patent/US20210040155A1/en active Pending
-
2021
- 2021-11-18 AU AU2021269411A patent/AU2021269411A1/en not_active Abandoned
-
2022
- 2022-03-24 JP JP2022048719A patent/JP2022084844A/ja active Pending
-
2024
- 2024-01-29 AU AU2024200528A patent/AU2024200528A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2725150C2 (ru) | 2020-06-30 |
AU2024200528A1 (en) | 2024-02-15 |
EP3450449A3 (en) | 2019-06-12 |
ES2693761T3 (es) | 2018-12-13 |
AU2014227712A1 (en) | 2015-10-01 |
RU2020120797A (ru) | 2020-07-02 |
AU2020203353A1 (en) | 2020-06-11 |
TR201815173T4 (tr) | 2018-11-21 |
JP2016516719A (ja) | 2016-06-09 |
US20210040155A1 (en) | 2021-02-11 |
JP2019172693A (ja) | 2019-10-10 |
AU2018256493A1 (en) | 2018-11-22 |
AU2021269411A1 (en) | 2021-12-16 |
EP2970388A1 (en) | 2016-01-20 |
JP6622690B2 (ja) | 2019-12-18 |
CA2906694A1 (en) | 2014-09-18 |
WO2014144260A1 (en) | 2014-09-18 |
RU2015145593A (ru) | 2017-04-24 |
US10196425B2 (en) | 2019-02-05 |
CN118240012A (zh) | 2024-06-25 |
CN118271400A (zh) | 2024-07-02 |
AU2014227712B2 (en) | 2018-08-02 |
EP3450449A2 (en) | 2019-03-06 |
US10858399B2 (en) | 2020-12-08 |
JP7046871B2 (ja) | 2022-04-04 |
EP2970388B1 (en) | 2018-07-25 |
CN105492456A (zh) | 2016-04-13 |
US20190092815A1 (en) | 2019-03-28 |
JP2022084844A (ja) | 2022-06-07 |
US20160017001A1 (en) | 2016-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216757A1 (zh) | 肽化合物 | |
ZA201505966B (en) | Peptides and compositions | |
SG11201602596UA (en) | Stabilized efinaconazole compositions | |
GB201304662D0 (en) | Compositions | |
EP2889350A4 (en) | ADHESIVE COMPOSITION | |
HK1220697A1 (zh) | 肽組合物 | |
GB201303771D0 (en) | Nanoparticles peptide compositions | |
GB201313615D0 (en) | Compositions | |
PT3061771T (pt) | Novo péptido unido a quatro epitopos ctl | |
HK1216715A1 (zh) | 基於血紅蛋白衍生肽的新型藥物組合物 | |
HK1211596A1 (en) | Peptide | |
ZA201505650B (en) | New compositions | |
GB201316463D0 (en) | Novel compositions | |
HK1211595A1 (en) | Peptide | |
HK1198769A1 (zh) | 新型肽 | |
IL244956B (en) | New peptide compositions | |
GB201320962D0 (en) | Compositions | |
GB201303787D0 (en) | Nanoparticle peptide compositions | |
GB201320959D0 (en) | Compositions | |
GB201312224D0 (en) | Compositions | |
GB201304927D0 (en) | Compositions | |
GB201316464D0 (en) | Novel compositions | |
GB201315598D0 (en) | Novel compositions |